Background In a recent study, we demonstrated the ability of lovastatin, a potent inhibitor of mevalonate synthesis, to inhibit the function of the epidermal growth factor receptor (EGFR). treatment, a therapeutically relevant dose, with two different VEGFR-2 inhibitors in HUVEC and the H28 and H2052 mesothelioma produced cell lines exhibited synergistic cytotoxicity as exhibited by… Continue reading Background In a recent study, we demonstrated the ability of lovastatin,